Medications for OUD: Extended-Release Naltrexone

Area of Science:

• Pharmacology
• Addiction Medicine
• Public Health

Background:

• Opioid use disorder (OUD) is a chronic, relapsing condition with severe health consequences.
• Extended-release naltrexone (XR-NTX) is an FDA-approved medication for OUD treatment.
• Evidence supports XR-NTX's efficacy and its use in diverse patient populations.

Purpose of the Study:

• To review the literature supporting XR-NTX for OUD.
• To identify limitations and challenges associated with XR-NTX treatment.
• To propose future research directions for XR-NTX in OUD management.

Main Methods:

• Literature review of randomized controlled trials and clinical studies.
• Analysis of XR-NTX efficacy in various populations and substance use disorders.
• Examination of treatment induction and discontinuation challenges.

Main Results:

• XR-NTX demonstrates efficacy comparable to buprenorphine in head-to-head trials.
• XR-NTX is effective in vulnerable populations including adolescents, criminal justice offenders, and HIV-infected patients.
• XR-NTX shows efficacy for alcohol use disorder and, with bupropion, methamphetamine use disorder.

Conclusions:

• XR-NTX is a first-line pharmacotherapeutic option for OUD with demonstrated efficacy.
• Managing opioid withdrawal during induction is crucial for successful XR-NTX initiation.
• Addressing challenges like relapse and overdose upon discontinuation is essential for long-term patient outcomes.